Biopol Chemicals appoints Vandan Vij Sarkar and Sukhomoy Das as Directors

Biopol Chemicals Limited has appointed Ms. Vandan Vij Sarkar and Mr. Sukhomoy Das as directors to its Board effective June 11, 2026, following a meeting of the Board of Directors. The appointments are aimed at strengthening the company's governance structure and leveraging the extensive experience of the new appointees in strategic management and corporate governance.

Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the appointment of Ms. Vandan Vij Sarkar (DIN: 02198810) as an Additional Director in the category of Non-Executive Director. She holds a Ph.D. in History from Pandit Ravishankar Shukla University and brings over 25 years of experience in the chemicals industry, with expertise in business development, strategic planning, and supply chain management. Ms. Sarkar is the spouse of Mr. Santanu Sarkar, Managing Director, and mother of Mr. Vedant Sarkar, Whole-time Director. She will hold office up to the date of the next General Meeting or within three months from the date of appointment, whichever is earlier, and will be liable to retire by rotation.

The Board also appointed Mr. Sukhomoy Das (DIN: 11761165) as an Additional Director in the capacity of Non-Executive Independent Director for a term of five consecutive years, subject to shareholder approval. Mr. Das is a highly experienced healthcare professional and governance expert with over 30 years of experience in clinical leadership, public policy, risk management, and corporate governance. He holds qualifications in Medicine from India and the United Kingdom and an LL.B. degree from the University of Strathclyde, Glasgow, UK. Since 1996, he has served in various senior clinical roles within NHS Scotland. He is currently serving as a Non-Executive Director and Whistleblowing Champion on the Board of NHS Ayrshire and Arran, Scotland. Mr. Das will hold office up to the date of the next General Meeting or within three months from the date of appointment, whichever is earlier. The Board confirmed that he fulfills the criteria of independence under the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. During his tenure, he will not be liable to retire by rotation.

Consequent to these appointments, the Board approved the reconstitution of various committees to ensure compliance with the Companies Act, 2013, and SEBI (LODR) Regulations, 2015. Mr. Sukhomoy Das has been appointed as the Chairman of the Nomination and Remuneration Committee and as a member of the Audit Committee. The meeting commenced at 03:00 P.M. and concluded at 04:30 P.M. on June 11, 2026.

Key Details of Appointments

Particulars	Vandan Vij Sarkar	Sukhomoy Das
Category	Non-Executive Director	Non-Executive Independent Director
DIN	02198810	11761165
Date of Appointment	June 11, 2026	June 11, 2026
Term	Up to next General Meeting or 3 months	5 consecutive years (subject to shareholder approval)

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.55%	-5.76%	-21.98%	-14.69%	-14.69%	-14.69%

Biopol Chemicals Limited has delivered impressive financial performance for the year ended March 31, 2026, with the Board of Directors approving the audited results at their meeting held on April 30, 2026. The company's statutory auditors, M/s. M B Jajodia & Associates, Chartered Accountants, have issued an unmodified opinion on the financial results.

Financial Performance Highlights

The company demonstrated strong operational performance across key financial metrics for FY26:

Financial Metric	FY26 (₹ Lakhs)	FY25 (₹ Lakhs)	Growth (%)
Revenue from Operations	8,114.33	4,922.13	+64.87%
Total Income	8,137.16	4,922.13	+65.34%
Net Profit	897.41	431.23	+108.12%
Profit Before Tax	1,205.84	578.04	+108.58%

The company's revenue from operations increased substantially to ₹8,114.33 lakhs in FY26 from ₹4,922.13 lakhs in the previous year, marking a growth of 64.87%. Total income for the year reached ₹8,137.16 lakhs, including other income of ₹22.83 lakhs.

Profitability Analysis

Biopol Chemicals showcased strong profitability improvements during FY26. The company's profit before tax more than doubled to ₹1,205.84 lakhs from ₹578.04 lakhs in FY25, representing a growth of 108.58%. After accounting for tax expenses of ₹308.43 lakhs, the net profit for the period stood at ₹897.41 lakhs, compared to ₹431.23 lakhs in the previous year.

Half-Year Performance

The second half of FY26 showed particularly strong performance:

Parameter	H2 FY26 (₹ Lakhs)	H2 FY25 (₹ Lakhs)	Growth (%)
Revenue from Operations	4,948.60	3,384.68	+46.22%
Net Profit	603.98	300.09	+101.24%

Balance Sheet Strength

The company's balance sheet reflects significant expansion and strengthening of its financial position as of March 31, 2026:

Balance Sheet Item	FY26 (₹ Lakhs)	FY25 (₹ Lakhs)
Total Assets	6,977.53	3,167.64
Shareholders' Funds	4,992.09	1,358.89
Property, Plant & Equipment	1,423.84	25.45
Trade Receivables	2,778.69	1,665.64

Earnings Per Share and Corporate Actions

The company reported earnings per share of ₹10.83 for FY26, compared to ₹5.45 in the previous year. The paid-up share capital increased to ₹1,080.54 lakhs from ₹791.10 lakhs, reflecting the company's capital expansion activities during the year.

Regulatory Compliance

Biopol Chemicals confirmed that it does not fall under the category of 'Large Corporate' as per SEBI circular requirements for the financial year ended March 31, 2026. The company operates as a single business segment and is listed on the SME platform of NSE, making it exempt from IND-AS applicability. The financial results are available on both the NSE website and the company's official website at biopolchemicals.com.